American Diabetes Association (with Valeant)
http://professional.diabetes.org/meeting/scientific-sessions/76th-scientific-sessions
Category: Archive News
31st Annual Clinical Conference on Diabetes
http://professional.diabetes.org/meeting/other/30th-annual-clinical-conference-diabetes
Cardiometabolic Health Congress Regional Conference Series
http://www.cardiometabolichealth.org/2016/regional/atlanta.html
Cleveland Clinic 21st Annual Diabetes Day
http://www.clevelandclinicmeded.com/live/courses/diabetesday/default.asp
Can deconstructing the biological clock help treat diabetes and cancer?
https://medcitynews.com/2015/08/can-deconstructing-the-biological-clock-help-treat-diabetes-and-cancer/comment-page-1/
Two Peer-Reviewed Studies Focusing on Unique Therapeutic Impact of VeroScience’s Cycloset Recently Published in Journal of Diabetes Research
http://www.prnewswire.com/news-releases/two-peer-reviewed-studies-focusing-on-unique-therapeutic-impact-of-verosciences-cycloset-recently-published-in-journal-of-diabetes-research-300098977.html
Cycloset (bromocriptine mesylate) Included in American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm
Cycloset is recommended for dual therapy for patients with entry HbA1c ≥ 7.5% SAN DIEGO & TIVERTON, R.I. –(BUSINESS WIRE)– Santarus, Inc. […]
Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for Cycloset® (bromocriptine mesylate) for the Management of Type 2 Diabetes
Experts conclude that favorable cardiovascular profile of Cycloset suggests it may be useful in the treatment of patients with type 2 diabetes […]
Santarus and VeroScience Announce Publication of Positive Data from Pivotal Cycloset® (bromocriptine mesylate) Efficacy Study
Cycloset add-on therapy provided significant improvement in glycemic control versus placebo in patients with type 2 diabetes poorly controlled on one or […]
Santarus and VeroScience Announce Publication of New Analysis of Cycloset (bromocriptine mesylate) Cardiovascular Data in the Journal of the American Heart Association
In assessing cardiovascular safety in type 2 diabetes subjects, Cycloset demonstrated a significant 52% relative risk reduction in cardiovascular events (composite endpoint […]
